Peptide Checkup

Lab testing · 24 pens · 24 certificates

Every lot.
Third-party tested.

A sample from every pen lot goes to an independent laboratory before the lot is listed. Purity by HPLC, identity by LC-MS, endotoxin by LAL — per component for the blends. The certificate is published against the batch number printed on the carton. Below: what each test does, how to read a certificate, and the certificate for each of the 24 pens.

Pens in the range
24
Certificates published
24
Components identity-confirmed
31
Lowest accepted purity
99.0%

01 — Methods

Three tests, one lot

Laboratory: Janoshik Analytical. It accepts public submissions, so any certificate can be re-run against the same batch number.

01

Purity · HPLC

Reverse-phase high-performance liquid chromatography separates the target compound from truncated, deletion and oxidised by-products and reports the target as a percentage of total peak area at 214–220 nm. In a blend, each component is resolved and reported separately.

ReportsTarget peak area % · per component in blends
Release limit≥ 99% for every component
CatchesTruncations, deletions, oxidation, dimerisation
Does not catchIdentity — a pure pen of the wrong compound still scores high

02

Identity · LC-MS

Liquid chromatography–mass spectrometry measures the molecular mass of each main peak and compares it with the theoretical mass of the labelled compound. A match within instrument tolerance confirms the pen contains what the carton says — every component of a blend, not just the largest.

ReportsObserved vs theoretical mass, per component
Release limitWithin ± 0.1% of theoretical (± 1 Da at 1 kDa)
CatchesWrong compound, wrong salt form, missing component in a blend
Does not catchLow-level impurities that co-elute with the main peak

03

Endotoxin · LAL

Limulus amoebocyte lysate assay for bacterial endotoxin, the pyrogenic residue left when gram-negative bacteria contaminate a process. Run on the finished solution in the pen and reported in endotoxin units per milligram of compound.

ReportsEU / mg
Release limit< 1.0 EU/mg (current lots < 0.5)
CatchesBacterial contamination during synthesis, fill or handling
Does not catchSterility of the finished pen — research pens are not medicines filled under GMP

02 — Reading a certificate

Six lines that matter

A specimen certificate for the current Tesamorelin lot, annotated. The same six fields appear on every pen page.

Certificate of analysis · specimen

Tesamorelin

Peptide pen · 20 mg / 3 mL

Lot AV-TES-2609-A
A
Batch
AV-TES-2609-A
B
Tested on
4 September 2026
C
Laboratory
Janoshik Analytical
D
Purity (HPLC)
99.2% (HPLC)
E
Identity (LC-MS)
Confirmed (LC-MS)
F
Endotoxin (LAL)
< 0.5 EU/mg

The live certificate for this lot sits on the pen page.

View
  1. A

    Match the batch

    The batch on the certificate must equal the batch printed on the carton and the pen label, and on the product page. If they differ, the certificate is not for your pen.

  2. B

    Check the date

    Tested on is the date the laboratory issued the report — not the fill date and not the ship date. We retest a lot if it has been in stock for more than nine months.

  3. C

    Read the lab, not the logo

    The laboratory is named and accepts samples from anyone, so a certificate can be re-run by a customer using the batch number.

  4. D

    Purity is one number per component

    99.3% means 0.7% of what was detected was not the target compound. Blends show one figure per component. Purity says nothing about how much is in the pen — the mass on the carton describes that.

  5. E

    Identity is yes or no

    Confirmed (LC-MS) means the observed mass matched the theoretical one. Anything else — 'consistent with', 'presumed' — should be read as unconfirmed. A blend certificate names every component confirmed.

  6. F

    Endotoxin is a ceiling

    < 0.5 EU/mg is a detection limit, not a measurement. Lower limits reflect a cleaner assay, not a purer compound.

03 — Blends

Tested per component

Wolverine, Klow, Glow and CagriSema put more than one compound in one pen. The certificate treats each as its own analyte: identity confirmed and purity reported for every component, endotoxin on the finished solution. Where the carton states only a combined amount, the per-component split is on the certificate.

Wolverine

2 components

BPC-157 + TB-500 · 40 mg / 3 mL

  • BPC-15720 mgIdentity · Purity
  • TB-50020 mgIdentity · Purity
Purity≥ 99.0% each component (HPLC)
IdentityAll components confirmed (LC-MS)

What testing cannot do is say anything about the combination: each component is graded on its own evidence record and the blend has not been studied in people.

Klow

4 components

GHK-Cu + BPC-157 + TB-500 + KPV · 80 mg / 3 mL

  • GHK-Cu50 mgIdentity · Purity
  • BPC-15710 mgIdentity · Purity
  • TB-50010 mgIdentity · Purity
  • KPV10 mgIdentity · Purity
Purity≥ 99.0% each component (HPLC)
IdentityAll components confirmed (LC-MS)

What testing cannot do is say anything about the combination: each component is graded on its own evidence record and the blend has not been studied in people.

Glow

3 components

GHK-Cu + BPC-157 + TB-500 · 70 mg / 3 mL

  • GHK-Cu50 mgIdentity · Purity
  • BPC-15710 mgIdentity · Purity
  • TB-50010 mgIdentity · Purity
Purity≥ 99.0% each component (HPLC)
IdentityAll components confirmed (LC-MS)

What testing cannot do is say anything about the combination: each component is graded on its own evidence record and the blend has not been studied in people.

CagriSema

2 components

Cagrilintide + semaglutide · 20 mg / 3 mL

  • CagrilintideSplit on certificateIdentity · Purity
  • SemaglutideSplit on certificateIdentity · Purity
Purity≥ 99.0% each component (HPLC)
IdentityAll components confirmed (LC-MS)

What testing cannot do is say anything about the combination: each component is graded on its own evidence record and the blend has not been studied in people.

04 — Batch numbering

AV-CCC-YYMM-L

Every lot number has four parts. It is printed on the carton, on the pen label, on the certificate and on the product page, and is what you quote if you want a laboratory to re-run the test.

AV

Brand

AERVYN — the manufacturer prefix on every lot we stock.

TES

Pen code

Three characters per pen — TES Tesamorelin, MOT MOTS-C, GHK GHK-Cu, NAD NAD+ and so on. Every pen's current lot, with its code, is in the certificates table below.

2609

Release

Year and month the lot was released: 26 = 2026, 09 = September.

A

Lot letter

Sequential within the month. A is the first lot released, B the second.

05 — Storage & shipping

Cold, dark, tracked

Unopened pen2–8 °C in the carton; use by the date on the label
In use2–8 °C between uses; cap on, out of direct light
FreezingDo not freeze. A pen that has frozen should not be used
Room temperatureShort excursions in transit only — not for storage
Copper peptide (GHK-Cu, Klow and Glow)As above; keep out of direct light between uses
In transitInsulated packaging with gel packs, tracked; shipped chilled
DispatchSame working day before 2 pm (UK)
Pen needlesNot included; a pen-needle compatibility note is in the box
Shipping and returns

06 — Certificates in force

24 pens, latest 4 Sept 2026

Generated from the catalogue. When a lot sells out its certificate stays here until the next lot replaces it.

PenBatchTested onLaboratoryPurityIdentityEndotoxin
AERVYN Tesamorelin peptide pen, 20 mg / 3 mL, with its carton
TesamorelinSingle compound		AV-TES-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
AERVYN MOTS-C peptide pen, 60 mg / 3 mL, with its carton
MOTS-CSingle compound		AV-MOT-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
AERVYN GHK-Cu peptide pen, 100 mg / 3 mL, with its carton
GHK-CuSingle compound		AV-GHK-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
AERVYN NAD+ peptide pen, 500 mg / 3 mL, with its carton
NAD+Single compound		AV-NAD-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
AERVYN Wolverine peptide pen, 40 mg / 3 mL, with its carton
Wolverine2 components		AV-WOL-2609-A4 Sept 2026Janoshik Analytical≥ 99.0% each component (HPLC)All components confirmed (LC-MS)< 0.5 EU/mg
AERVYN Klow peptide pen, 80 mg / 3 mL, with its carton
Klow4 components		AV-KLW-2609-A4 Sept 2026Janoshik Analytical≥ 99.0% each component (HPLC)All components confirmed (LC-MS)< 0.5 EU/mg
AERVYN Glow peptide pen, 70 mg / 3 mL, with its carton
Glow3 components		AV-GLW-2609-A4 Sept 2026Janoshik Analytical≥ 99.0% each component (HPLC)All components confirmed (LC-MS)< 0.5 EU/mg
AERVYN KPV peptide pen, 10 mg / 3 mL, with its carton
KPVSingle compound		AV-KPV-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
AERVYN Retatrutide (R3T) peptide pen, 40 mg / 3 mL, with its carton
Retatrutide (R3T)Single compound		AV-R3T-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
BPC-1571 PEN · 10 MG / 3 MLBPC-157Single compoundAV-BPC-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
CAGRI1 PEN · 20 MG / 3 MLCagriSema2 componentsAV-CGS-2609-A4 Sept 2026Janoshik Analytical≥ 99.0% each component (HPLC)All components confirmed (LC-MS)< 0.5 EU/mg
CJC-12951 PEN · 10 MG / 3 MLCJC-1295 (no DAC)Single compoundAV-CJC-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
EPITALON1 PEN · 50 MG / 3 MLEpitalonSingle compoundAV-EPI-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
FOXO41 PEN · 10 MG / 3 MLFOXO4-DRISingle compoundAV-FOX-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
GNRH1 PEN · 10 MG / 3 MLGonadorelinSingle compoundAV-GNR-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
IPA1 PEN · 10 MG / 3 MLIpamorelinSingle compoundAV-IPA-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
LIRA1 PEN · 18 MG / 3 MLLiraglutideSingle compoundAV-LIR-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
LL-371 PEN · 10 MG / 3 MLLL-37Single compoundAV-LL3-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
PT-1411 PEN · 10 MG / 3 MLPT-141Single compoundAV-PT1-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
SEMA1 PEN · 10 MG / 3 MLSemaglutideSingle compoundAV-SEM-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
SERMO1 PEN · 10 MG / 3 MLSermorelinSingle compoundAV-SER-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
TB-5001 PEN · 10 MG / 3 MLTB-500Single compoundAV-TB5-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
TA11 PEN · 10 MG / 3 MLThymosin Alpha-1Single compoundAV-TA1-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg
TIRZ1 PEN · 30 MG / 3 MLTirzepatideSingle compoundAV-TIR-2609-A4 Sept 2026Janoshik Analytical99.2% (HPLC)Confirmed (LC-MS)< 0.5 EU/mg

07 — What testing cannot tell you

The limits, stated

  1. 01Testing confirms the identity and purity of what is in the pen. It says nothing about safety or effectiveness in humans — that is what the evidence record is for.
  2. 02A certificate describes a sample from the lot, not every pen in it. Fill-volume variation between pens is not measured.
  3. 03For blends, each component is tested on its own. The combination is not tested as a combination, and nobody has studied these combinations in people.
  4. 04Research pens are not manufactured as medicines. They are not filled under GMP, and no regulator has inspected the process.
  5. 05We pay the laboratory. The results are independent of us in method and reporting, but the commercial relationship exists and you should know it.
Evidence directoryHow we grade evidence